Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
pozelimab is an approved drug (FDA (2023))
Compound class:
Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
|
Immunopharmacology Comments |
An anti-C5 mAb that is proposed to treat inflammatory disorders that are driven complement pathway activation. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
CHAPLE disorder; CD55 deficiency with hyper-activation of complement, angiopathic thrombosis, and severe protein-losing enteropathy (PLE) |
OMIM:
226300 Orphanet: ORPHA566175 |
Pozelimab is FDA aproved to treat children and adults with CHAPLE disorder. |